Skip to content

The use of hyaluronic acid in the treatment of abnormal narrowing of the spinal canal in the lumbar spine

The use of hyaluronic acid in the symptomatic treatment of foraminal stenosis of the lumbar spine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN14155217
Enrollment
40
Registered
2022-05-16
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pain complaints as a result of lumbar foraminal stenosis Musculoskeletal Diseases

Interventions

The project involves the administration of a single dose of a hybrid form of hyaluronic acid called Sinovial HL, under ultrasound guidance, in the zone of expected compression of the nerve root from t

Sponsors

Sutherland Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Clinical symptoms of radicular pain in the lumbar region 2. MRI confirmed recital stenosis of degenerative origin 3. No other spine diseases (post-traumatic, systemic inflammatory diseases, cancer, birth defects) 4. Adults consenting to the injection 5. Mental contact ensuring cooperation in the period of neuromobilization

Exclusion criteria

Exclusion criteria: 1. Neurological deficit 2. The presence of other spine diseases (post-traumatic, systemic inflammatory diseases, neoplasms, birth defects) 3. Refusal to consent to the injection 4. Anticoagulants, other injection contraindications 5. Impeded contact with the patient, not promising cooperation during the period of neuromobilization

Design outcomes

Primary

MeasureTime frame
1. Pain assessed using the Numerical Rating Scale (NRS, 1-10) at baseline and 1, 2, and 3 months after the intervention 2. Pain assessed using the Roland – Morris scale at baseline and 1, 2, and 3 months after the intervention 3. Pain assessed using the Straight Leg Raise Test (SLR test) at baseline and 1, 2, and 3 months after the intervention

Secondary

MeasureTime frame
Disability assessed using the Oswestry Low Back Pain Disability Questionnaire at baseline and 1, 2, and 3 months after the intervention

Countries

Poland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026